ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Ejaculation‑sparing thulium laser enucleation of the prostate (ES‑ThuLEP)
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 187225" data-attributes="member: 13851"><p><strong>Ejaculation‑sparing thulium laser enucleation of the prostate (ES‑ThuLEP): <span style="color: rgb(184, 49, 47)">outcomes on a large cohort </span></strong></p><p><strong><span style="color: rgb(184, 49, 47)"></span></strong></p><p><strong><span style="color: rgb(184, 49, 47)"></span></strong></p><p><strong><span style="color: rgb(184, 49, 47)"></span></strong></p><p><strong><span style="color: rgb(184, 49, 47)"></span></strong></p><p><strong><span style="color: rgb(184, 49, 47)"></span></strong></p><p><strong><span style="color: rgb(184, 49, 47)">Abstract </span></strong></p><p><strong></strong></p><p><strong>Purpose</strong> <em><span style="color: rgb(184, 49, 47)">To assess the effects of a new ejaculation-sparing thulium laser enucleation of the prostate </span><span style="color: rgb(0, 0, 0)">(ES-ThuLEP) </span><span style="color: rgb(184, 49, 47)">technique on sexual functions and micturition, in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia </span><span style="color: rgb(0, 0, 0)">(BPH)</span><span style="color: rgb(184, 49, 47)"> and to evaluate how the surgical technique of ES-ThuLEP can lead to ejaculation preservation. </span></em></p><p></p><p><strong>Methods</strong> A prospective study was carried out between January 2015 and January 2018 on patients with a surgical indication for BPH, who wished to preserve ejaculation. The patients were treated with ES-ThuLEP and were evaluated before and 3 and 6 months after surgery. Three validated questionnaires (ICIQ-MLUTSsex, IIEF-5, and IPSS) were used to assess changes in ejaculation, erectile function, and urinary symptoms. Uroflowmetry (Qmax and Qavg), post-void residual volume, and voided volume were also evaluated, to assess micturition improvement. Patients with moderate to severe erectile dysfunction were excluded. Statistical analysis was performed with the Student’s t-test, Chi-square test, and logistic regression analysis.</p><p></p><p><strong>Results</strong> Two hundred and eighty-three patients were enrolled. Ejaculation was spared in 203 and 219 patients at 3 and 6 months after surgery. No significant differences were observed between erectile function before and after surgery: baseline IIEF-5=16.2±4.47 vs 16.7±2.9 (p=0.419) and 17.7±3.2 (p=0.410) at 3 and 6 months. Significant improvement in urinary symptoms was achieved: baseline IPSS=19.4±7.24 vs 5.8±4.3 (p=0.032) and 3.9±4.1 (p=0.029) at 3 and 6 months.</p><p></p><p><strong>Conclusion</strong> <em><span style="color: rgb(184, 49, 47)">ES-ThuLEP effectively preserved ejaculation in over two-thirds of the patients without compromising micturition improvement or erectile function. ES-ThuLEP could be a valid treatment option for BPH in young and sexually active men.</span></em></p><p></p><p></p><p></p><p></p><p><strong>Introduction </strong></p><p></p><p>Benign prostatic hyperplasia (BPH) is a common condition in aging men, which leads to lower urinary tract symptoms (LUTS) and sexual dysfunction, negatively impacting on the patients’ quality of life [1, 2]. <span style="color: rgb(184, 49, 47)"><em>Despite allowing relief from LUTS, classical medical, and surgical treatments for BPH have always been burdened by important consequences on the patients’ ejaculatory function.</em></span> Over the past three decades research has focused on the development of new surgical strategies to reduce morbidity and complications of conventional surgical procedures, such as transurethral resection of the prostate (TURP) and open prostatectomy (OP), but in most cases overlooking the impact on the patients’ ejaculatory function. <em><span style="color: rgb(184, 49, 47)">Thanks to the advent of laser technologies, endoscopic enucleation of the prostate (EEP) techniques have been developed [3, 4]. These mimick an OP, which is achieved endoscopically, using a laser, or a bipolar resector to enucleate the adenoma, imitating the use of the finger during OP, but maintaining minimal invasiveness of TURP. Holmium laser enucleation of the prostate (HoLEP) [5] and thulium laser enucleation of the prostate (ThuLEP) [6] is the most demanded laser EEP techniques (LEEP). Both determine the excellent resolution of LUTS and improvement in voiding parameters, comparable to those of TURP and OP, but with reduced morbidity, catheterization time, and hospital stay. Moreover, they allow treating prostates of virtually all sizes [7–10].</span></em> Reasons for which, EAU Guidelines recommend to resort to OP only in the absence of an EEP system [11]. Despite the well-documented advantages of LEEP techniques over TURP and OP, they have not been able to overcome postoperative ejaculatory dysfunction (EjD) [12, 13].</p><p></p><p><em><span style="color: rgb(184, 49, 47)">The only recommended ejaculation-sparing (ES) procedure today [11], is the prostatic urethral lift, which consists of the positioning of suture-based implants under cystoscopic guidance, to compress the lateral lobes [14]. Despite being a valid treatment option, especially in elderly and frail patients [15] and despite excellent outcomes on ejaculation, it does not achieve the same micturition improvement of TURP [16]. Moreover, it is only recommended for small prostates (<70 ccs) and it does not remove the hyperplastic tissue. </span></em><span style="color: rgb(44, 130, 201)"><em>Other novel, minimally invasive, non-ablative surgical techniques such as Aquablation, Rezum, and prostatic artery embolization, despite presenting more favorable outcomes on ejaculation compared to TURP, are still considered “under investigation” by EAU Guidelines, due to the lack of randomized controlled trials, with a long-term follow-up, investigating their safety and efficacy [11, 17]. </em></span></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong>Conclusions</strong></span></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>ES-ThuLEP allows to effectively preserve ejaculation in more than two-thirds of the patients, no matter what prostate size, without compromising micturition improvement or erectile function and maintaining a low complication rate, making it a valid treatment alternative for young and sexually active men suffering from BPH. </strong></span></p></blockquote><p></p>
[QUOTE="madman, post: 187225, member: 13851"] [B]Ejaculation‑sparing thulium laser enucleation of the prostate (ES‑ThuLEP): [COLOR=rgb(184, 49, 47)]outcomes on a large cohort Abstract [/COLOR] Purpose[/B] [I][COLOR=rgb(184, 49, 47)]To assess the effects of a new ejaculation-sparing thulium laser enucleation of the prostate [/COLOR][COLOR=rgb(0, 0, 0)](ES-ThuLEP) [/COLOR][COLOR=rgb(184, 49, 47)]technique on sexual functions and micturition, in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia [/COLOR][COLOR=rgb(0, 0, 0)](BPH)[/COLOR][COLOR=rgb(184, 49, 47)] and to evaluate how the surgical technique of ES-ThuLEP can lead to ejaculation preservation. [/COLOR][/I] [B]Methods[/B] A prospective study was carried out between January 2015 and January 2018 on patients with a surgical indication for BPH, who wished to preserve ejaculation. The patients were treated with ES-ThuLEP and were evaluated before and 3 and 6 months after surgery. Three validated questionnaires (ICIQ-MLUTSsex, IIEF-5, and IPSS) were used to assess changes in ejaculation, erectile function, and urinary symptoms. Uroflowmetry (Qmax and Qavg), post-void residual volume, and voided volume were also evaluated, to assess micturition improvement. Patients with moderate to severe erectile dysfunction were excluded. Statistical analysis was performed with the Student’s t-test, Chi-square test, and logistic regression analysis. [B]Results[/B] Two hundred and eighty-three patients were enrolled. Ejaculation was spared in 203 and 219 patients at 3 and 6 months after surgery. No significant differences were observed between erectile function before and after surgery: baseline IIEF-5=16.2±4.47 vs 16.7±2.9 (p=0.419) and 17.7±3.2 (p=0.410) at 3 and 6 months. Significant improvement in urinary symptoms was achieved: baseline IPSS=19.4±7.24 vs 5.8±4.3 (p=0.032) and 3.9±4.1 (p=0.029) at 3 and 6 months. [B]Conclusion[/B] [I][COLOR=rgb(184, 49, 47)]ES-ThuLEP effectively preserved ejaculation in over two-thirds of the patients without compromising micturition improvement or erectile function. ES-ThuLEP could be a valid treatment option for BPH in young and sexually active men.[/COLOR][/I] [B]Introduction [/B] Benign prostatic hyperplasia (BPH) is a common condition in aging men, which leads to lower urinary tract symptoms (LUTS) and sexual dysfunction, negatively impacting on the patients’ quality of life [1, 2]. [COLOR=rgb(184, 49, 47)][I]Despite allowing relief from LUTS, classical medical, and surgical treatments for BPH have always been burdened by important consequences on the patients’ ejaculatory function.[/I][/COLOR] Over the past three decades research has focused on the development of new surgical strategies to reduce morbidity and complications of conventional surgical procedures, such as transurethral resection of the prostate (TURP) and open prostatectomy (OP), but in most cases overlooking the impact on the patients’ ejaculatory function. [I][COLOR=rgb(184, 49, 47)]Thanks to the advent of laser technologies, endoscopic enucleation of the prostate (EEP) techniques have been developed [3, 4]. These mimick an OP, which is achieved endoscopically, using a laser, or a bipolar resector to enucleate the adenoma, imitating the use of the finger during OP, but maintaining minimal invasiveness of TURP. Holmium laser enucleation of the prostate (HoLEP) [5] and thulium laser enucleation of the prostate (ThuLEP) [6] is the most demanded laser EEP techniques (LEEP). Both determine the excellent resolution of LUTS and improvement in voiding parameters, comparable to those of TURP and OP, but with reduced morbidity, catheterization time, and hospital stay. Moreover, they allow treating prostates of virtually all sizes [7–10].[/COLOR][/I] Reasons for which, EAU Guidelines recommend to resort to OP only in the absence of an EEP system [11]. Despite the well-documented advantages of LEEP techniques over TURP and OP, they have not been able to overcome postoperative ejaculatory dysfunction (EjD) [12, 13]. [I][COLOR=rgb(184, 49, 47)]The only recommended ejaculation-sparing (ES) procedure today [11], is the prostatic urethral lift, which consists of the positioning of suture-based implants under cystoscopic guidance, to compress the lateral lobes [14]. Despite being a valid treatment option, especially in elderly and frail patients [15] and despite excellent outcomes on ejaculation, it does not achieve the same micturition improvement of TURP [16]. Moreover, it is only recommended for small prostates (<70 ccs) and it does not remove the hyperplastic tissue. [/COLOR][/I][COLOR=rgb(44, 130, 201)][I]Other novel, minimally invasive, non-ablative surgical techniques such as Aquablation, Rezum, and prostatic artery embolization, despite presenting more favorable outcomes on ejaculation compared to TURP, are still considered “under investigation” by EAU Guidelines, due to the lack of randomized controlled trials, with a long-term follow-up, investigating their safety and efficacy [11, 17]. [/I][/COLOR] [COLOR=rgb(0, 0, 0)][B]Conclusions[/B][/COLOR] [COLOR=rgb(184, 49, 47)][B]ES-ThuLEP allows to effectively preserve ejaculation in more than two-thirds of the patients, no matter what prostate size, without compromising micturition improvement or erectile function and maintaining a low complication rate, making it a valid treatment alternative for young and sexually active men suffering from BPH. [/B][/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Ejaculation‑sparing thulium laser enucleation of the prostate (ES‑ThuLEP)
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top